SITC2024: The paring of CD200 humanized cancer cells with CD200 and CD200R double humanized mice for the preclinical evaluation of the combination of anti-human CD200 antibodies and immune checkpoint drugs

SITC2024: The paring of CD200 humanized cancer cells with CD200 and CD200R double humanized mice for the preclinical evaluation of the combination of anti-human CD200 antibodies and immune checkpoint drugs

Summary:

• B-hCD200/hCD200R mice express human CD200 and CD200R.
• B-hCD200 MC38 cells express human CD200.
• Tumor growth of B-hCD200 MC38 and wild-type MC38 cells was comparable in B-hCD200/hCD200R mice.
• Combined anti-human CD200 and anti-mouse PD-1 antibodies effectively inhibited B-hCD200 MC38 tumor growth in B-hCD200/hCD200R mice.
• B-hCD200/hCD200R mice paired with B-hCD200 MC38 cells provide a model to evaluate the in vivo efficacy of anti-human CD200 antibodies and immune checkpoint therapies.